- Home
- BANR vs GLPG Comparison
BANR vs GLPG Comparison
Compare BANR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANR
- GLPG
- Stock Information
- Founded
- BANR 1890
- GLPG 1999
- Country
- BANR United States
- GLPG Belgium
- Employees
- BANR N/A
- GLPG N/A
- Industry
- BANR Major Banks
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- BANR Finance
- GLPG Health Care
- Exchange
- BANR Nasdaq
- GLPG Nasdaq
- Market Cap
- BANR 2.2B
- GLPG 1.9B
- IPO Year
- BANR 1995
- GLPG 2005
- Fundamental
- Price
- BANR $68.68
- GLPG $30.32
- Analyst Decision
- BANR Buy
- GLPG Sell
- Analyst Count
- BANR 6
- GLPG 4
- Target Price
- BANR $70.40
- GLPG $25.33
- AVG Volume (30 Days)
- BANR 227.0K
- GLPG 240.0K
- Earning Date
- BANR 07-16-2025
- GLPG 07-23-2025
- Dividend Yield
- BANR 2.79%
- GLPG N/A
- EPS Growth
- BANR 5.82
- GLPG N/A
- EPS
- BANR 5.09
- GLPG N/A
- Revenue
- BANR $614,045,000.00
- GLPG $311,493,731.00
- Revenue This Year
- BANR $3.72
- GLPG $0.78
- Revenue Next Year
- BANR $5.38
- GLPG N/A
- P/E Ratio
- BANR $13.49
- GLPG N/A
- Revenue Growth
- BANR 3.98
- GLPG 18.32
- 52 Week Low
- BANR $50.61
- GLPG $22.36
- 52 Week High
- BANR $78.05
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- BANR 69.63
- GLPG 67.62
- Support Level
- BANR $66.34
- GLPG $28.21
- Resistance Level
- BANR $69.51
- GLPG $30.64
- Average True Range (ATR)
- BANR 2.10
- GLPG 0.52
- MACD
- BANR 0.46
- GLPG 0.23
- Stochastic Oscillator
- BANR 91.25
- GLPG 91.29
About BANR Banner Corporation
Banner Corp is a bank holding company. It wholly owns one subsidiary bank, Banner Bank. The Bank's primary business is that of traditional banking institutions, accepting deposits and originating loans in locations surrounding its offices in Washington, Oregon, California, Idaho and Utah. Banner Bank also actively participates in the secondary loan markets, engaging in mortgage banking operations largely through the origination and sale of one to four family residential loans.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.